
If food suppliers weren’t already spooked by the surge in demand for weight loss-aiding drugs like Wegovy and Ozempic, they’ve just been given a fresh $900 million reminder of why they should be.
Danish drugmaker Novo Nordisk has the figures to prove growing interest in weight loss-aiding medication was far from just hype.